| Followers | 54 |
| Posts | 6684 |
| Boards Moderated | 0 |
| Alias Born | 01/11/2017 |
Thursday, August 19, 2021 6:36:44 AM
I think stock manipulation can take on many colors-
For example- a company could have a two-time felon who filed bankruptcy twice. This CEO could/would never purchase a share on the open market but instead would unjustly enrich himself, TWICE, only to be sued and forced to return those shares.
Said CEO would also acquire “bonus shares” from an acquisition that wasn’t put to a vote AND get this is: fires the guy he bought the company from claiming “for cause”. But then said fired person sues Cytodyn and wins! The company is forced to pay $7M in damages and additional stock.
Imagine if that CEO was actively pumping the stock with terms like “Golden Quarter” and “Triple Digit Stock”, while then selling $14M in shares and the CFO is dumping at the same time.
Then, imagine releasing amazing results that are really a mirage. The statements are deemed so dishonest and abhorrent that the FDA issues a stinging rebuke that the CEO openly agrees with on a call.
I couldn’t dream this up and thought wow, this must be part of the 13d group but after further investigation I find IT IS THE CURRENT CEO!! Wow, was I shocked.
But I’d love to hear more about the short seller theory! Because I think the actions above are enough, coupled with no cash, failed trials, RTF on a BLA submission would be enough to sink the stock! But apparently it’s a giant short-seller conspiracy.
Edit: If this is so well known as a poster suggested, why is this comedy about the 12d group perpetuated. What is laid out above is FACT! Documented FACT!!
Next!
Appreciate the insight
Grip
For example- a company could have a two-time felon who filed bankruptcy twice. This CEO could/would never purchase a share on the open market but instead would unjustly enrich himself, TWICE, only to be sued and forced to return those shares.
Said CEO would also acquire “bonus shares” from an acquisition that wasn’t put to a vote AND get this is: fires the guy he bought the company from claiming “for cause”. But then said fired person sues Cytodyn and wins! The company is forced to pay $7M in damages and additional stock.
Imagine if that CEO was actively pumping the stock with terms like “Golden Quarter” and “Triple Digit Stock”, while then selling $14M in shares and the CFO is dumping at the same time.
Then, imagine releasing amazing results that are really a mirage. The statements are deemed so dishonest and abhorrent that the FDA issues a stinging rebuke that the CEO openly agrees with on a call.
I couldn’t dream this up and thought wow, this must be part of the 13d group but after further investigation I find IT IS THE CURRENT CEO!! Wow, was I shocked.
But I’d love to hear more about the short seller theory! Because I think the actions above are enough, coupled with no cash, failed trials, RTF on a BLA submission would be enough to sink the stock! But apparently it’s a giant short-seller conspiracy.
Edit: If this is so well known as a poster suggested, why is this comedy about the 12d group perpetuated. What is laid out above is FACT! Documented FACT!!
Next!
Appreciate the insight
Grip
Recent CYDY News
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
